文献速递心脑血管急症消化、代谢与肾脏急症

激素避孕与非甾体抗炎药联用与静脉血栓栓塞风险:全国队列研究

Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study.
PubMed 文献 · BMJ · 2023-09-06
一句话结论丹麦全国队列显示,使用NSAIDs与静脉血栓栓塞风险升高相关,联用高风险激素避孕时风险更高。

该全国队列纳入1996至2017年丹麦15-49岁无血栓、癌症等病史的女性2 029 065例,随访21.0百万人年,发生8710例静脉血栓栓塞事件。与不使用NSAIDs相比,使用NSAIDs在未用激素避孕女性中调整发病率比为7.2(95%CI 6.0-8.5),高风险激素避孕联用者为11.0(9.6-12.6),中风险为7.9(5.9-10.6),低/无风险为4.5(2.6-8.1)。作者认为,需要同时使用激素避孕和规律使用NSAIDs的女性应据此给予建议。

要点

  • 使用NSAIDs与育龄女性静脉血栓栓塞风险升高相关,未用激素避孕者调整发病率比7.2(95%CI 6.0-8.5)。
  • 联用高风险激素避孕者使用NSAIDs的调整发病率比为11.0(95%CI 9.6-12.6),高于未用激素避孕者。
  • 联用中风险激素避孕者调整发病率比为7.9(95%CI 5.9-10.6),低/无风险者为4.5(95%CI 2.6-8.1)。
  • NSAID治疗第一周每10万女性额外静脉血栓栓塞事件:未用激素避孕4例(95%CI 3-5),高风险23例(19-27),中风险11例(7-15),低/无风险3例(0-5)。
  • 作者认为,需要同时使用激素避孕和规律使用NSAIDs的女性应据此给予建议。

适用人群与场景

  • 1996至2017年居住在丹麦的所有15-49岁女性,且无任何静脉或动脉血栓事件、癌症、易栓症、子宫切除、双侧卵巢切除、绝育或不孕治疗病史(n=2 029 065)。

处置流程与药物剂量

  • 作者认为,需要同时使用激素避孕和规律使用NSAIDs的女性应据此给予建议。

研究设计与关键结果

  • 研究设计:全国队列研究,基于丹麦全国登记数据。
  • 共纳入2 029 065名女性,随访21.0百万人年,发生8710例静脉血栓栓塞事件。
  • 与不使用NSAIDs相比,使用NSAIDs的调整静脉血栓栓塞发病率比:未用激素避孕女性7.2(95%CI 6.0-8.5),使用高风险激素避孕女性11.0(95%CI 9.6-12.6),使用中风险激素避孕女性7.9(95%CI 5.9-10.6),使用低/无风险激素避孕女性4.5(95%CI 2.6-8.1)。
  • NSAID治疗第一周每10万女性额外静脉血栓栓塞事件数(与不使用NSAIDs相比):未用激素避孕女性4例(95%CI 3-5),使用高风险激素避孕女性23例(95%CI 19-27),使用中风险激素避孕女性11例(95%CI 7-15),使用低/无风险激素避孕女性3例(95%CI 0-5)。

证据类型、等级与局限

  • 证据类型:全国队列研究(基于丹麦全国登记数据)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需要同时使用激素避孕和规律使用NSAIDs的女性应据此给予建议。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To study the influence of concomitant use of hormonal contraception and non-steroidal anti-inflammatory drugs (NSAIDs) on the risk of venous thromboembolism.

DESIGN: Nationwide cohort study.

SETTING: Denmark through national registries.

PARTICIPANTS: All 15-49 year old women living in Denmark between 1996 and 2017 with no medical history of any venous or arterial thrombotic event, cancer, thrombophilia, hysterectomy, bilateral oophorectomy, sterilisation, or infertility treatment (n=2 029 065).

MAIN OUTCOME MEASURE: A first time discharge diagnosis of lower limb deep venous thrombosis or pulmonary embolism.

RESULTS: Among 2.0 million women followed for 21.0 million person years, 8710 venous thromboembolic events occurred. Compared with non-use of NSAIDs, use of NSAIDs was associated with an adjusted incidence rate ratio of venous thromboembolism of 7.2 (95% confidence interval 6.0 to 8.5) in women not using hormonal contraception, 11.0 (9.6 to 12.6) in women using high risk hormonal contraception, 7.9 (5.9 to 10.6) in those using medium risk hormonal contraception, and 4.5 (2.6 to 8.1) in users of low/no risk hormonal contraception. The corresponding numbers of extra venous thromboembolic events per 100 000 women over the first week of NSAID treatment compared with non-use of NSAIDs were 4 (3 to 5) in women not using hormonal contraception, 23 (19 to 27) in women using high risk hormonal contraception, 11 (7 to 15) in those using medium risk hormonal contraception, and 3 (0 to 5) in users of low/no risk hormonal contraception.

CONCLUSIONS: NSAID use was positively associated with the development of venous thromboembolism in women of reproductive age. The number of extra venous thromboembolic events with NSAID use compared with non-use was significantly larger with concomitant use of high/medium risk hormonal contraception compared with concomitant use of low/no risk hormonal contraception. Women needing both hormonal contraception and regular use of NSAIDs should be advised accordingly.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Meaidi A, Mascolo A, Sessa M, et al. Venous thromboembolism with use of hormonal contraception and non-steroidal anti-inflammatory drugs: nationwide cohort study. BMJ. 2023. PMID: 37673431. doi:10.1136/bmj-2022-074450

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。